[go: up one dir, main page]

RU94031161A - Фармацевтическая композиция и способ ее получения, способ лечения нарушений, развивающихся вследствие нейродегенеративных процессов - Google Patents

Фармацевтическая композиция и способ ее получения, способ лечения нарушений, развивающихся вследствие нейродегенеративных процессов

Info

Publication number
RU94031161A
RU94031161A RU94031161/14A RU94031161A RU94031161A RU 94031161 A RU94031161 A RU 94031161A RU 94031161/14 A RU94031161/14 A RU 94031161/14A RU 94031161 A RU94031161 A RU 94031161A RU 94031161 A RU94031161 A RU 94031161A
Authority
RU
Russia
Prior art keywords
obtaining
pharmaceutical composition
treating disorders
neurodegenerative processes
developing due
Prior art date
Application number
RU94031161/14A
Other languages
English (en)
Other versions
RU2125448C1 (ru
Inventor
Мадьяр Кальман
Гаал Йожеф
Сираки Иштван
Лендьел Йожеф
Сабо Анна
Мармароши Каталин
Хермец Иштван
Сатмари Иштван
Терек Золтан
Кермеци Петер
Original Assignee
Хиноин Дьедьсер еш Ведьесети Термекек Дьяра РТ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU914060A external-priority patent/HUT63579A/hu
Application filed by Хиноин Дьедьсер еш Ведьесети Термекек Дьяра РТ filed Critical Хиноин Дьедьсер еш Ведьесети Термекек Дьяра РТ
Publication of RU94031161A publication Critical patent/RU94031161A/ru
Application granted granted Critical
Publication of RU2125448C1 publication Critical patent/RU2125448C1/ru

Links

Claims (1)

  1. Изобретение относится к двухфазным фармацевтическим композициям, содержащим ингибитор МАО и ингибитор поглощения в качестве активного ингредиента в сочетании со стандартными фармацевтическими добавками. Указанные композиции могут быть использованы для лечений нейродегенеративных заболеваний. В этих композициях, в качестве активного ингредиента, т.е. ингибитора МАО и ингибитора поглощения, могут быть использованы N-(1-фенилизопропил)-N-метилпропиламин или N-(4-фторфенил)-изопроп-1-ил-Н-метилпропиламин, или их соли, оптически активные изомеры или метаболиты.
RU94031161A 1991-12-20 1992-12-18 Фармацевтическая композиция и способ ее получения, способ лечения нарушений, развивающихся вследствие нейродегенеративных процессов RU2125448C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU914060A HUT63579A (en) 1991-12-20 1991-12-20 Process for producing double-phase pharmaceutical compositions suitable for treating diseases occurring during neurodegenerative processes
HU4060/91 1992-12-08
PCT/HU1992/000060 WO1993012775A1 (en) 1991-12-20 1992-12-18 Pharmaceutical composition and process for the preparation thereof

Publications (2)

Publication Number Publication Date
RU94031161A true RU94031161A (ru) 1996-03-27
RU2125448C1 RU2125448C1 (ru) 1999-01-27

Family

ID=10966728

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94031161A RU2125448C1 (ru) 1991-12-20 1992-12-18 Фармацевтическая композиция и способ ее получения, способ лечения нарушений, развивающихся вследствие нейродегенеративных процессов

Country Status (27)

Country Link
US (1) US5589513A (ru)
EP (1) EP0617615A1 (ru)
JP (1) JPH07502730A (ru)
KR (1) KR940703655A (ru)
AU (1) AU677170B2 (ru)
BG (1) BG98827A (ru)
BR (1) BR9206950A (ru)
CA (1) CA2125776A1 (ru)
CZ (1) CZ147494A3 (ru)
EC (1) ECSP930933A (ru)
EE (1) EE03015B1 (ru)
FI (1) FI942932A0 (ru)
HU (2) HUT63579A (ru)
IL (1) IL104150A (ru)
LT (1) LT3119B (ru)
LV (1) LV10386B (ru)
MY (1) MY111055A (ru)
NO (1) NO942303D0 (ru)
NZ (1) NZ246384A (ru)
PH (1) PH31073A (ru)
PL (1) PL172048B1 (ru)
RO (1) RO115785B1 (ru)
RU (1) RU2125448C1 (ru)
SI (1) SI9200404A (ru)
SK (1) SK74494A3 (ru)
WO (1) WO1993012775A1 (ru)
ZA (1) ZA929883B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
DE4432610C1 (de) * 1994-09-13 1996-02-01 Knoll Ag Verfahren zur Herstellung von Selegilin-Hydrochlorid
CA2212412A1 (en) * 1995-02-10 1996-08-15 The University Of Toronto Innovations Foundation Deprenyl compounds for treatment of glaucoma
JP4499208B2 (ja) * 1998-10-29 2010-07-07 株式会社フジモト・コーポレーション 新規な光学活性アミノペンタン誘導体
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
HUP9902482A2 (hu) * 1999-07-22 2002-04-29 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. P-fluoro-selegilin alkalmazása neuroprotektív gyógyszerkészítmények előállítására
EP2053033A1 (en) * 2007-10-26 2009-04-29 Bayer Schering Pharma AG Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
DE102009045056A1 (de) * 2009-09-28 2011-03-31 Henkel Ag & Co. Kgaa Fleckenvorbehandlungsmittel
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
AU2019308326A1 (en) 2018-07-20 2021-03-18 Lipocine Inc. Liver disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1227447B (de) * 1962-03-30 1966-10-27 Chinoin Gyogyszer Es Vegyeszet Verfahren zur Herstellung von Phenylisopropylaminen
HU193662B (en) * 1983-12-20 1987-11-30 Chinoin Gyogyszer Es Vegyeszet Process for producing synergetic pharmaceutical composition of antidepressive aktivity
HU207282B (en) * 1984-05-31 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing phenyl-alkyl-amine derivatives and pharmaceutical compositions containing them
ATE55245T1 (de) * 1986-04-16 1990-08-15 Asta Pharma Ag Synergistische kombination von amantadin und selegilin.
HU207280B (en) * 1986-09-25 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing new phenyl-alkyl-amines and pharmaceutical compositions containing them
HU197510B (en) * 1986-12-19 1989-04-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
GB8807504D0 (en) * 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
CA2037178A1 (en) * 1990-02-28 1991-08-29 Albert Walter Brzeczko Deprenyl/l-dopa/carbidopa pharmaceutical composition
GB9011767D0 (en) * 1990-05-25 1990-07-18 Britannia Pharmaceuticals Ltd Pharmaceutical compositions
US5169868A (en) * 1991-03-01 1992-12-08 University Of Saskatchewan Aliphatic propargylamines as specific mao-b inhibitors
US5444095A (en) * 1991-04-04 1995-08-22 University Of Toronto, Innovations Foundation Use of deprenyl to rescue damaged nerve cells
HU209605B (en) * 1991-04-15 1994-09-28 Chinoin Gyogyszer Es Vegyeszet Process for production of wather-free transdermal preparation
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals

Similar Documents

Publication Publication Date Title
RU94031161A (ru) Фармацевтическая композиция и способ ее получения, способ лечения нарушений, развивающихся вследствие нейродегенеративных процессов
NO961687L (no) Nye (R)-5-karbamoyl-8-fluor-3-N,N-disubstituerte-amino-3,4-dihydro-2H-1-benzopyraner
DK0495776T3 (da) Stabiliserende nitrogenoxid/primær amin-komplekser, der er anvendelige som cardiovaskulære midler
MX9100990A (es) Compuesto monohidrato de furoato de mometasona,al procedimiento para su preparacion y a las composiciones farmaceuticas
DE3484573D1 (de) Durchdringende topische pharmazeutische zusammensetzungen mit gehalt an n-(2-hydroxyethyl)-pyrrolidon.
BR9406979A (pt) Composto,composicão farmaceutica para tratar uma doenca inflamatória suscetivel de tratamento com um agente anti- inflamatório nao esteroidal processos para tratar uma doenca inflamatória e para preparar um composto sal famacéuticamente aceitável uso de um composto composicão farmaceutica anti-inflamatória nao esteroidal
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
DE69716810D1 (de) 2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
BR9507073A (pt) Composto processos para preparar o mesmo e para tratar uma doença no sistema nervoso central composiçao farmacêutica e uso do composto
BG98827A (en) Pharmaceutical composition and method for its preparation
EP0699439A3 (en) Treatment of diseases caused by sebum with inhibitors of acyl CoA cholesterol acyltransferase
MX24839A (es) 3-arilcarbonil-1-aminoalquilo-1h-indoles, proceso para su preparacion y composicion farmaceutica quelos contiene.
DK0888323T3 (da) Dihydrobenzofuran og beslægtede forbindelser, der er nyttige som antiinflammatoriske midler
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
RU93053905A (ru) Оксипуриновые нуклеозиды и родственные им соединения, а также их ацильные производные для улучшения гемопоэза, фармацевтическая композиция и способ лечения и/или профилактики
UA26403A (uk) Похідhі n-заміщеhого 4-феhіл-4-піперидиhкарбоксаміду та їх фармацевтичhо прийhятhі солі, що проявляють аhестезувальhу та аhальгезувальhу дію, спосіб їх одержаhhя та фармацевтичhа композиція
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
BR9611276A (pt) Composto formulação farmacêutica processo para tratamento ou profilaxia de doenças ou condições de seres humanos e uso de um composto
DK0634396T3 (da) Aminosyrederivater og deres anvendelse som enkeltfalinaseinhibitorer
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE48759T1 (de) Behandlung von anfaellen und hierfuer nuetzliche pharmazeutische zusammensetzungen.
ITRM910730A1 (it) Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali.
NO970573D0 (no) Ylidenforbindelser og deres fremstilling
NO953892D0 (no) Imidazolokinoksalinon-derivater som EAA-antagonister
DE3380923D1 (de) Pharmazeutische zusammensetzungen zur behandlung von stoerungen, bedingt durch humanendrogen.